- Report
- October 2023
- 159 Pages
Global
From €4318EUR$4,500USD£3,734GBP
- Report
- February 2024
- 138 Pages
Middle East, Africa
From €1439EUR$1,500USD£1,245GBP
- Report
- August 2022
- 115 Pages
Global
From €4318EUR$4,500USD£3,734GBP
- Report
- May 2022
- 152 Pages
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
- Report
- September 2022
- 341 Pages
Global
From €3684EUR$3,840USD£3,186GBP
The Lung Disorder market within the context of Pulmonary Medicine is a highly specialized field of medicine that focuses on the diagnosis and treatment of diseases and disorders of the lungs. This includes conditions such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary hypertension, and lung cancer. Pulmonologists are the primary healthcare professionals who specialize in the diagnosis and treatment of these conditions. They use a variety of diagnostic tests, such as imaging studies, pulmonary function tests, and bronchoscopy, to diagnose and treat lung disorders. Treatment options may include medications, lifestyle changes, and surgery.
Some companies in the Lung Disorder market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more